



EXPRESS MAIL NO. EV335608228US

06-07-04

Jfw

<b>TRANSMITTAL FORM</b>  (To be used for all correspondence after initial filing)	Application Number	10/627,586
	Filing Date	July 25, 2003
	First Named Inventor	Khalid Mekouar
	Art Unit	1614
	Examiner Name	
	Attorney Docket No.	660081.442

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> 10 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Jeffrey C. Pepe, Ph.D. Reg. No. 46,985	Customer Number <b>00500</b>
Signature		
Date	June 3, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name		
Signature		Date:

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1487648



EXPRESS MAIL NO. EV335608228US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Khalid Mikouar at al.  
Application No. : 10/627,586  
Filed : July 25, 2003  
For : ANTI-VIRAL 7-DEAZA D-NUCLEOSIDES AND USES THEREOF  
Art Unit : 1614  
Docket No. : 660081.442  
Date : June 3, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 CFR 1.98, are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

We hereby certify that each of the references set forth on the attached form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Supplemental Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

  
\_\_\_\_\_  
Jeffrey C. Pepe, Ph.D.  
Registration No. 46,985

JCP:ljt

Enclosures:

Postcard  
Transmittal Form  
Form PTO-1449  
Cited References (10)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

\487642

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

660081.442

APPLICATION NO.

10/627,586

## SUPPLEMENTAL

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Khalid Mekouar et al.

FILING DATE

July 25, 2003

GROUP ART UNIT

1614

## U.S. PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AC	EP 286028 A	10/12/88	EPO		
AD	EP 866070 A1	09/23/98	EPO		
AE	WO 02/057287	07/25/02	WIPO		
AF	WO 02/057425	07/25/02	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AG	Bergstrom, D.E. et al., "Antiviral Activity of C-5 Substituted Tubercidin Analogues," <i>Journal of Medicinal Chemistry</i> 27(3): 285-292, 1984.
AH	Bhattacharya, B.K. et al., "Synthesis and Anti-DNA Viral Activities <i>in Vitro</i> of Certain 2,4-Disubstituted-7-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)pyrrolo[2,3- <i>d</i> ]pyrimidine Nucleosides," <i>Journal of Medicinal Chemistry</i> 38(20): 3957-3966, 1995.
AI	Cui, L. et al., "Effect of $\beta$ -Enantiomeric and Racemic Nucleoside Analogues on Mitochondrial Functions in HEPG2 Cells," <i>Biochemical Pharmacology</i> 52: 1577-1584, 1996.
AJ	Ojwang, J.O. et al., "Inhibition of Episomal Hepatitis B Virus DNA In Vitro by 2,4-Diamino-7-(w-Deoxy-2-Fluoro- $\beta$ -D-Arabinofuranosyl)-Pyrrolo[2,3- <i>d</i> ]Pyrimidine," <i>Antimicrobial Agents and Chemotherapy</i> 39(11): 2570-2573, November 1995.
AK	Pudlo, J.S. et al., "Synthesis and Antiviral Activity of Certain 4- and 4,5-Disubstituted 7-[(2-Hydroxyethoxy)methyl]pyrrolo[2,3- <i>d</i> ]pyrimidines," <i>Journal of Medicinal Chemistry</i> 31(11): 2086-2092, 1988.
AL	Robins, M.J. et al., "Nucleic Acid Related Compounds. 88. Efficient Conversion of Ribonucleosides into Their 2',3'-Anhydro, 2'(and 3')-Deoxy, 2',3'-Didehydro-2',3'-dideoxy, and 2',3'-Dideoxynucleoside Analogues," <i>Journal of Organic Chemistry</i> 60(24): 7902-7908, 1995.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).